Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Jonas S. Heitmann, MD, Daniela Dörfel, MD, Sabine Kayser, MD, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, MD, Wolfgang Bethge, MD, Ludger Grosse-Hovest, Martin Steiner, Melanie Märklin, PhD, Juliane S. Walz, MD, Richard F. Schlenk, Gundram Jung, MD, Helmut R. Salih

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139493

Published: 2020

Journal Articles

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sabine Kayser, MD, Jonas S. Heitmann, MD, Daniela Dörfel, MD, Felicitas Thol, MD, Michael Heuser, MD, Melanie Märklin, PhD, Carsten Müller-Tidow, MD, Martin Steiner, Ludger Grosse-Hovest, Gundram Jung, MD, Richard F. Schlenk, MD, Helmut R. Salih, MD

Blood (2019) 134 (Supplement_1): 3928.

https://doi.org/10.1182/blood-2019-125327

Published: 2019

Journal Articles

Induction of NK and T Cell Immune Responses Against Leukemia Cells By Bispecific NKG2D-CD16 and -CD3 Fusion Proteins

Samuel Koerner, Lothar Kanz, MD, Ludger Grosse-Hovest, Gundram Jung, Helmut R Salih, MD

Blood (2015) 126 (23): 2558.

https://doi.org/10.1182/blood.V126.23.2558.2558

Published: 2015

Journal Articles

Induction of NK Cell Reactivity Against Myeloid Leukemia By a Novel Fc-Optimized CD133 Antibody

Kathrin Rothfelder, Samuel Koerner, Maya Andre, Julia Leibold, Philaretos Kousis, Hans-Jörg Bühring, Sebastian P. Haen, MD, Ayline Kuebler, Lothar Kanz, MD, Ludger Grosse-Hovest, Gundram Jung, Helmut R Salih, MD

Blood (2015) 126 (23): 3793.

https://doi.org/10.1182/blood.V126.23.3793.3793

Published: 2015

Journal Articles

Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

Samuel Koerner, Julia Leibold, Ludger Grosse-Hovest, PhD, Hans-Joerg Buehring, PhD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R. Salih, MD

Blood (2014) 124 (21): 2309.

https://doi.org/10.1182/blood.V124.21.2309.2309

Published: 2014

Journal Articles

An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells

Kathrin Rothfelder, Julia Leibold, Ludger Grosse-Hovest, PhD, Hans-Joerg Buehring, PhD, Gundram Jung, MD, Lothar Kanz, MD, Helmut R Salih, MD

Blood (2014) 124 (21): 2739.

https://doi.org/10.1182/blood.V124.21.2739.2739

Published: 2014

Journal Articles

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

Helmut R. Salih, MD, Martin Hofmann, Ludger Grosse-Hovest, PhD, Tina Nuebling, PhD, Maximilian Bamberg, Steffen Aulwurm, PhD, Hans-Joerg Buehring, PHD, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Gundram Jung, MD

Blood (2013) 122 (21): 1454.

https://doi.org/10.1182/blood.V122.21.1454.1454

Published: 2013

Journal Articles

From Bedside To Bench: Molecular Benchmarking Of An Fc-Optimized CD19 Antibody Used In Treatment Of Relapsed and Refractory Pediatric B-Lineage Acute Lymphoblastic Leukemia

Ursula J.E. Seidel, Ludger Grosse-Hovest, PhD, Patrick Schlegel, MD, Martin Hofmann, Friedhelm R. Schuster, MD, Kai-Erik Witte, Steffen Aulwurm, PhD, Rouwen Teltschik, Elwira Pyz, PhD, Hans-Georg Rammensee, Gundram Jung, MD, Rupert Handgretinger, Prof., Peter Lang, MD

Blood (2013) 122 (21): 3905.

https://doi.org/10.1182/blood.V122.21.3905.3905

Published: 2013

Journal Articles

Bimodal Induction of NK Cell Reactivity Against Acute Myeloid (AML) and Chronic Lymphoid Leukemia (CLL) by Fc-Engineered GITR-Fc Fusion Proteins.

Julia Steinbacher, Benjamin J Schmiedel, PhD, Antje Werner, Tina Nuebling, PhD, Corina Buechele, Ludger Grosse-Hovest, PhD, Lothar Kanz, MD, Helmut R Salih, MD

Blood (2012) 120 (21): 2143.

https://doi.org/10.1182/blood.V120.21.2143.2143

Published: 2012

Journal Articles

Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia

Peter Lang, MD, Heiko-Manuel Teltschik, MD, Patrick Schlegel, MD, Ursula Seidel, Ludger Grosse-Hovest, PhD, Steffen Aulwurm, PhD, Martin Hofmann, Rouwen Teltschik, Kai Witte, MD, Hans-Georg Rammensee, Prof., Gundram Jung, MD, Rupert Handgretinger, MD

Blood (2012) 120 (21): 581.

https://doi.org/10.1182/blood.V120.21.581.581

Published: 2012

Journal Articles

Induction of NK Cell Reactivity in Breast Cancer by Fc-Engineered NKG2D-Ig Fusion Proteins

Stefanie Raab, Julia Steinbacher, Ludger Grosse-Hovest, PhD, Benjamin J Schmiedel, PhD, Alexander Steinle, PhD, Lothar Kanz, MD, Helmut R Salih, MD

Blood (2012) 120 (21): 253.

https://doi.org/10.1182/blood.V120.21.253.253

Published: 2012

Journal Articles

Induction of NK Cell Reactivity Against AML Cells by Fc-Engineered RANK-Ig Fusion Proteins.

Tina Nuebling, PhD, Benjamin J Schmiedel, PhD, Miyuki Azuma, MD, PhD, Pascal Schneider, PhD, Ludger Grosse-Hovest, PhD, Lothar Kanz, MD, Helmut R Salih, MD

Blood (2012) 120 (21): 2625.

https://doi.org/10.1182/blood.V120.21.2625.2625

Published: 2012

Journal Articles

Fc-Engineered NKG2D-IgG1 Fusion Proteins Target Leukemia Cells for Antibody-Dependent Cellular Cytotoxicity (ADCC) of NK Cells

Julia Hilpert, Katrin Baltz-Ghahremanpour, Benjamin J Schmiedel, Lothar Kanz, MD, Gundram Jung, Ludger Grosse-Hovest, Helmut R. Salih, MD

Blood (2011) 118 (21): 1537.

https://doi.org/10.1182/blood.V118.21.1537.1537

Published: 2011

Journal Articles

Targeting RANKL for Immunotherapy of Multiple Myeloma

Benjamin J Schmiedel, Ludger Grosse-Hovest, Stefanie Bugl, M. Sc., Hans-Georg Kopp, MD, Stefan Wirths, MD, Bernd J Pichler, Miyuki Azuma, Pascal Schneider, Lothar Kanz, MD, Gundram Jung, Helmut R. Salih, MD

Blood (2011) 118 (21): 2905.

https://doi.org/10.1182/blood.V118.21.2905.2905

Published: 2011

Journal Articles

Inhibition of Antibody Production in Vitro with Bispecific CD20 X CD95 Antibodies

Kristina Nalivaiko, Martin Hofmann, Ludger Grosse-Hovest, Peter H Krammer, Hans-Georg Rammensee, Helmut R. Salih, MD, Gundram Jung

Blood (2011) 118 (21): 1114.

https://doi.org/10.1182/blood.V118.21.1114.1114

Published: 2011

Journal Articles

RANKL Expressed by Acute Myeloid Leukemia Cells Impairs NK Cell-Mediated Immune Surveillance

Benjamin J Schmiedel, Constantin M Wende, Tina Baessler, Carolin Scheible, Stefan Wirths, Miyuki Azuma, Pascal Schneider, Ludger Grosse-Hovest, Lothar Kanz, Helmut R Salih

Blood (2010) 116 (21): 2164.

https://doi.org/10.1182/blood.V116.21.2164.2164

Published: 2010

Journal Articles

Generation, Functional Characterization and Clinical Application of a Novel Fc-Optimized Anti-FLT3 Antibody for the Treatment of Acute Myeloid Leukemia

Helmut R. Salih, MD, Tina Baessler, Martin Hofmann, Ludger Grosse-Hovest, Maximilian Bamberg, Steffen Aulwurm, Hans-Joerg Buehring, Lothar Kanz, MD, Gundram Jung

Blood (2010) 116 (21): 2187.

https://doi.org/10.1182/blood.V116.21.2187.2187

Published: 2010

Journal Articles

Fc-Engineered RANK-Fc Fusion Proteins for Neutralization of Soluble RANKL and Induction of Antibody-Dependent Cellular Cytotoxicity (ADCC) Against Multiple Myeloma

Benjamin J Schmiedel, Carolin Scheible, Tina Baessler, Constantin M Wende, Stefan Wirths, Miyuki Azuma, Pascal Schneider, Ludger Grosse-Hovest, Lothar Kanz, Helmut R Salih

Blood (2010) 116 (21): 3039.

https://doi.org/10.1182/blood.V116.21.3039.3039

Published: 2010

Journal Articles

A Fc-Engineered RANK-Fc Fusion Protein Neutralizes Soluble RANK Ligand and Targets Malignant Hematopoietic Cells for NK Cell Reactivity.

Benjamin J Schmiedel, Tina Baessler, Carolin Scheible, Constantin M Wende, Miyuki Azuma, Pascal Schneider, Lothar Kanz, MD, Ludger Grosse-Hovest, Helmut R Salih, MD

Blood (2009) 114 (22): 411.

https://doi.org/10.1182/blood.V114.22.411.411

Published: 2009

Journal Articles

TREM-1 ligand expression on platelets enhances neutrophil activation

Philipp Haselmayer, Ludger Grosse-Hovest, Philipp von Landenberg, Hansjörg Schild, Markus P. Radsak

Blood (2007) 110 (3): 1029–1035.

https://doi.org/10.1182/blood-2007-01-069195

Published: 2007

Includes: Supplemental data

NARROW

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Induction of NK and T Cell Immune Responses Against Leukemia Cells By Bispecific NKG2D-CD16 and -CD3 Fusion Proteins

Induction of NK Cell Reactivity Against Myeloid Leukemia By a Novel Fc-Optimized CD133 Antibody

Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells

Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM)

From Bedside To Bench: Molecular Benchmarking Of An Fc-Optimized CD19 Antibody Used In Treatment Of Relapsed and Refractory Pediatric B-Lineage Acute Lymphoblastic Leukemia

Bimodal Induction of NK Cell Reactivity Against Acute Myeloid (AML) and Chronic Lymphoid Leukemia (CLL) by Fc-Engineered GITR-Fc Fusion Proteins.

Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia

Induction of NK Cell Reactivity in Breast Cancer by Fc-Engineered NKG2D-Ig Fusion Proteins

Induction of NK Cell Reactivity Against AML Cells by Fc-Engineered RANK-Ig Fusion Proteins.

Fc-Engineered NKG2D-IgG1 Fusion Proteins Target Leukemia Cells for Antibody-Dependent Cellular Cytotoxicity (ADCC) of NK Cells

Targeting RANKL for Immunotherapy of Multiple Myeloma

Inhibition of Antibody Production in Vitro with Bispecific CD20 X CD95 Antibodies

RANKL Expressed by Acute Myeloid Leukemia Cells Impairs NK Cell-Mediated Immune Surveillance

Generation, Functional Characterization and Clinical Application of a Novel Fc-Optimized Anti-FLT3 Antibody for the Treatment of Acute Myeloid Leukemia

Fc-Engineered RANK-Fc Fusion Proteins for Neutralization of Soluble RANKL and Induction of Antibody-Dependent Cellular Cytotoxicity (ADCC) Against Multiple Myeloma

A Fc-Engineered RANK-Fc Fusion Protein Neutralizes Soluble RANK Ligand and Targets Malignant Hematopoietic Cells for NK Cell Reactivity.

TREM-1 ligand expression on platelets enhances neutrophil activation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only